Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Genetic testing for effective Herceptin therapy].

Toru Watanabe1, Noriyuki Katsumata, Masashi Ando

  • 1Department of Medical Oncology, National Cancer Center Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Breast cancer (Tokyo, Japan)·2026
Same author

Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial.

Breast cancer (Tokyo, Japan)·2026
Same author

Survival in the SONIA Trial.

JAMA oncology·2026
Same author

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Breast cancer research : BCR·2026
Same author

Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness).

Breast cancer (Tokyo, Japan)·2026

Herceptin, a monoclonal antibody, shows tyrosine kinase modulation improves cancer therapy outcomes. Developing diagnostic algorithms for HER2 testing is crucial for targeted cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Context:

  • Herceptin (trastuzumab) exemplifies successful targeted cancer therapy by modulating tyrosine kinase activity.
  • HER2 overexpression in 30% of breast cancer patients drives the development of targeted treatments.
  • Biologic therapy interest and target identification facilitate clinical trial accrual.

Purpose:

  • To highlight the clinical success of Herceptin as a proof-of-concept for tyrosine kinase modulation in cancer therapy.
  • To discuss the challenges in HER2/neu oncogene testing, including discrepancies between immunohistochemistry and fluorescence in situ hybridization.
  • To propose the development of an algorithm for standardized HER2 testing to aid clinical interpretation.

Summary:

  • Herceptin's success validates monoclonal antibodies targeting tyrosine kinases for improved cancer outcomes.

Related Experiment Videos

  • Accurate HER2 overexpression detection is critical, but diagnostic methods like IHC and FISH show variability.
  • Standardized testing algorithms are needed to simplify interpretation and guide treatment decisions.

    • Impact:

    • Herceptin's development provides a paradigm for targeted cancer therapy.
    • Experience with HER2 testing informs future strategies for molecularly targeted drug development and clinical application.
    • Improved diagnostic strategies will enhance the efficacy of personalized cancer medicine.